From somatostatin to octreotide LAR: Evolution of a somatostatin analogue

Current Medical Research and Opinion

Volumn 25, Issue 12, 2009, Pages 2989-2999

  Anthony, Lowell ^a   Freda, Pamela U ^b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Acromegaly; Carcinoid; NETs; Neuroendocrine tumors; Octreotide; Sandostatin; Somatostatin analogue

Indexed keywords

ANGIOPEPTIN; AUTOGEL; BICARBONATE; CABERGOLINE; FLUOROURACIL; GASTRIN; GLUCAGON; GROWTH HORMONE; INSULIN; MOTILIN; OCTREOTIDE; PANCREAS POLYPEPTIDE; PEGVISOMANT; SECRETIN; SOMATOMEDIN C; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ABDOMINAL CRAMP; ACROMEGALY; ANTINEOPLASTIC ACTIVITY; BILIARY TRACT DISEASE; CANCER CONTROL; CARCINOID; CARDIOVASCULAR FUNCTION; CHOLELITHIASIS; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CYTOREDUCTIVE SURGERY; DIARRHEA; DISEASE CONTROL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULARY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; FLATULENCE; GALLSTONE; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; GROWTH HORMONE RELEASE; HEADACHE; HORMONE ACTION; HUMAN; INJECTION SITE PAIN; LIVER CELL CARCINOMA; LONG ACTING RELEASE; LOOSE FECES; MIDGUT; NAUSEA; NEUROENDOCRINE SYSTEM; NEUROENDOCRINE TUMOR; OBESITY; OVARY POLYCYSTIC DISEASE; PATIENT COMPLIANCE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; SYSTEMIC SCLEROSIS;

ACROMEGALY; ANIMALS; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; OCTREOTIDE; RETROSPECTIVE STUDIES; SOMATOSTATIN;

EID: 72549097292     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903328959     Document Type: Review

References (86)

1. Webb SM. Quality of life in acromegaly. Neuroendocrinology 2006;83:224-229
2. Modlin IM, Latich I, Kidd M, et al. Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol 2006;4:526-547
3. Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004;25:102-152 (Pubitemid 38269977)
4. Melmed S. Acromegaly. N Engl J Med 1990;322:966-977
5. Melmed S. Medical progress: Acromegaly. N Engl J Med 2006;355:2558-2573
6. Sanno N, Teramoto A, Osamura RY, et al. Pathology of pituitary tumors. Neurosurg Clin N Am 2003;14:25-39, vi
7. Biermasz NR, Romijn JA, Pereira AM, et al. Current pharmacotherapy for acromegaly: a review. Expert Opin Pharmacother 2005;6:2393-2405
8. Kleinberg DL. Primary therapy for acromegaly with somatostatin analogs and a discussion of novel peptide analogs. Rev Endocr Metab Disord 2005;6:29-37 (Pubitemid 40558135)
9. Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982;31:1133-1140 (Pubitemid 13243115)
10. Delaunoit T, Rubin J, Neczyporenko F, et al. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors. Mayo Clin Proc 2005;80:502-506 (Pubitemid 40471383)
11. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004;25:458-511 (Pubitemid 38780668)
12. Robertson RG, Geiger WJ, Davis NB. Carcinoid tumors. Am Fam Physician 2006;74:429-434
13. Anthony LB, Kang T, Shyr Y. Malignant carcinoid syndrome: survival in the octreotide LAR era. Proc Am Soc Clin Oncol 2005;abst 4084
14. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003;24:28-47
15. Cozzi R, Attanasio R. Octreotide for acromegaly. Expert Rev Endocrinol Metab 2007;2:129-145
16. Reisine T, Bell GI. Molecular properties of somatostatin receptors. Neuroscience 1995;67:777-790
17. Bronstein MD. Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome. Front Horm Res 2006;35:129-134 (Pubitemid 44024246)
18. Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 1997;53:681-699
19. Astruc B, Marbach P, Bouterfa H, et al. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol 2005;45:836-844 (Pubitemid 40875336)
20. Chen T, Miller TF, Prasad P, et al. Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. J Clin Pharmacol 2000;40:475-481 (Pubitemid 32010015)
21. Melmed S, Vance ML, Barkan AL, et al. Current status and future opportunities for controlling acromegaly. Pituitary 2002;5:185-196 (Pubitemid 36656432)
22. Melmed S, Casanueva F, Cavagnini F, et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005;153:737-740 (Pubitemid 43020222)
23. Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Arch Intern Med 1991;151:1573-1578
24. Ezzat S, Snyder PJ, Young WF, et al. Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med 1992;117:711-718
25. Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients-a clinical research center study. J Clin Endocrinol Metab 1995;80:2768-2775
26. McKeage K, Cheer S, Wagstaff AJ. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs 2003;63:2473-2499 (Pubitemid 37392914)
27. Cozzi R, Attanasio R, Montini M, et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 2003;88:3090-3098
28. Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to 9 years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006;91:1397-1403
29. Lancranjan I, Atkinson AB. Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group. Pituitary 1999;1:105-114
30. Freda PU, Katznelson L, van der Lely AJ, et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005;90:4465-4473 (Pubitemid 41159328)
31. Murray RD, Melmed S. A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly. J Clin Endocrinol Metab 2008;93:2957-2968
32. Colao A, Marzullo P, Ferone D, et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab 2000;85:3132-3140 (Pubitemid 30944515)
33. Colao A, Cuocolo A, Marzullo P, et al. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. J Clin Endocrinol Metab 2001;86:1551-1557 (Pubitemid 32374902)
34. Ferone D, Colao A, van der Lely AJ, et al. Pharmacotherapy or surgery as primary treatment for acromegaly? Drugs Aging 2000;17:81-92
35. Colao A, Cappabianca P, Caron P, et al. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clin Endocrinol (Oxf) 2009;70:757-768
36. Petrossians P, Borges-Martins L, Espinoza C, et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 2005;152:61-66 (Pubitemid 40185454)
37. Colao A, Attanasio R, Pivonello R, et al. Partial surgical removal of GH-secreting pituitary tumors enhances the response to somatostatin analogues in acromegaly. J Clin Endocrinol Metab 2006;91:85-92 (Pubitemid 43069122)
38. Losa M, Mortini P, Urbaz L, et al. Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. J Neurosurg 2006;104:899-906 (Pubitemid 43824739)
39. Abe T, Ludecke DK. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 2001;145:137-145 (Pubitemid 32707599)
40. Biermasz NR, van Dulken H, Roelfsema F. Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls. J Clin Endocrinol Metab 1999;84:3551-3555 (Pubitemid 30645204)
41. Colao A, Ferone D, Cappabianca P, et al. Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 1997;82:3308-3314 (Pubitemid 27419077)
42. Carlsen SM, Lund-Johansen M, Schreiner T, et al. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 2008;93:2984-2990
43. Biermasz NR, van den Oever NC, Frolich M, et al. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. Clin Endocrinol (Oxf) 2003;58:288-295 (Pubitemid 36308116)
44. Jenkins PJ, Akker S, Chew SL, et al. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. Clin Endocrinol (Oxf) 2000;53:719-724 (Pubitemid 32096683)
45. Turner HE, Thornton-Jones VA, Wass JA. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clin Endocrinol (Oxf) 2004;61:224-231
46. Ronchi CL, Rizzo E, Lania AG, et al. Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. Eur J Endocrinol 2008;158:19-25 (Pubitemid 351211036)
47. Lal A, Chen H. Treatment of advanced carcinoid tumors. Curr Opin Oncol 2006;18:9-15
48. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999;17:600-606 (Pubitemid 29075248)
49. Dueno MI, Bai JC, Santangelo WC, et al. Effect of somatostatin analog on water and electrolyte transport and transit time in human small bowel. Dig Dis Sci 1987;32:1092-1096
50. Viola KV, Sosa JA. Current advances in the diagnosis and treatment of pancreatic endocrine tumors. Curr Opin Oncol 2005;17:24-27 (Pubitemid 40179907)
51. Butturini G, Bettini R, Missiaglia E, et al. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer 2006;13:1213-1221 (Pubitemid 46212575)
52. Rinke A, Muller H-H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study of the effect of Octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. J Clin Oncol 2009;27:4656-4663
53. Arnold R, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study of the effect of Octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. ASCO GI Cancers Symposium abst 121, 2009 Abstract
54. Arnold R, Muller H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. J Clin Oncol, ASCO Annual Meeting Proceedings 2009;27:Abst 4508
55. NCCN Practice Guidelines in Oncology, v.1.2009. Neuroendocrine tumors. 2009. Available at: http://www.nccn.org
56. Ruszniewski P, Ish-Shalom S, Wymenga M, et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 2004;80:244-251 (Pubitemid 40187010)
57. Eriksson B, Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol 1999;10(Suppl 2):S31-8 (Pubitemid 29288528)
58. Oberg K. Established clinical use of octreotide and lanreotide in oncology. Chemotherapy 2001;47(Suppl 2):40-53 (Pubitemid 32238643)
59. Corleto VD, Angeletti S, Schillaci O, et al. Long-term octreotide treatment of metastatic carcinoid tumor. Ann Oncol 2000;11:491-493 (Pubitemid 30333557)
60. Janson ET, Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 1993;32:225-229
61. Koelz A, Kraenzlin M, Gyr K, et al. Escape of the response to a long-acting somatostatin analogue (SMS 201-995) in patients with VIPoma. Gastroenterology 1987;92:527-531 (Pubitemid 17231739)
62. Lamberts SW, Pieters GF, Metselaar HJ, et al. Development of resistance to a long-acting somatostatin analogue during treatment of two patients with metastatic endocrine pancreatic tumours. Acta Endocrinol (Copenh) 1988;119:561-566
63. Ruszniewski P, Ducreux M, Chayvialle JA, et al. Treatment of the carcinoid syndrome with the long-acting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 1996;39:279-283 (Pubitemid 26276007)
64. Ricci S, Antonuzzo A, Galli L, et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol 2000;23:412-415 (Pubitemid 32429157)
65. Janmohamed S, Bloom SR. Carcinoid tumours. Postgrad Med J 1997;73:207-214
66. Garland J, Buscombe JR, Bouvier C, et al. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. Aliment Pharmacol Ther 2003;17:437-444 (Pubitemid 36259407)
67. O'Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000;88:770-776 (Pubitemid 30091095)
68. Welin SV, Janson ET, Sundin A, et al. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol 2004;151:107-112 (Pubitemid 39117371)
69. Redfern JS, Fortuner WJ. Octreotide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management. Am J Gastroenterol 1995;90:1042-1052
70. Catnach SM, Anderson JV, Fairclough PD, et al. Effect of octreotide on gall stone prevalence and gall bladder motility in acromegaly. Gut 1993;34:270-273
71. Paisley AN, Roberts ME, Trainer PJ. Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems. Clin Endocrinol (Oxf) 2007;66:723-726
72. Weckbecker G, Raulf F, Stolz B, et al. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther 1993;60:245-264 (Pubitemid 24117378)
73. Froidevaux S, Eberle AN. Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers 2002;66:161-183 (Pubitemid 35285217)
74. Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 2006;17:1733-1742 (Pubitemid 44884046)
75. Schally AV, Szepeshazi K, Nagy A, et al. New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs. Cell Mol Life Sci 2004;61:1042-1068 (Pubitemid 38626508)
76. Slijkhuis WA, Stadheim L, Hassoun ZM, et al. Octreotide therapy for advanced hepatocellular carcinoma. J Clin Gastroenterol 2005;39:333-338 (Pubitemid 40393250)
77. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, et al. The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology 2002;49:1245-1250 (Pubitemid 35052791)
78. Kwekkeboom DJ, Teunissen JJ, Kam BL, et al. Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues. Hematol Oncol Clin North Am 2007;21:561-573 (Pubitemid 46843516)
79. De Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002;32:133-140 (Pubitemid 34311079)
80. Rosenoff SH, Gabrail NY, Conklin R, et al. A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial. J Support Oncol 2006;4:289-294 (Pubitemid 44203632)
81. Zidan J, Haim N, Beny A, et al. Octreotide in the treatment of severe chemotherapy-induced diarrhea. Ann Oncol 2001;12:227-229 (Pubitemid 32223873)
82. Baillie-Johnson HR. Octreotide in the management of treatment-related diarrhoea. Anticancer Drugs 1996;7(Suppl 1):11-15
83. Nikou GC, Toumpanakis C, Katsiari C, et al. Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients. J Clin Rheumatol 2007;13:119-123 (Pubitemid 46884197)
84. Gambineri A, Patton L, De Iasio R, et al. Efficacy of octreotide-LAR in dieting women with abdominal obesity and polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:3854-3862 (Pubitemid 41058143)
85. Lustig RH, Greenway F, Velasquez-Mieyer P, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion. Int J Obes (Lond) 2006;30:331-341 (Pubitemid 43237691)
86. Ramage JK, Davies AH, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005;54(Suppl 4):iv1-16 (Pubitemid 40695259)